INTRODUCTION
Tadalafil TDL is a poorly water soluble drug which was approved recently for the management and treatment of male erectile dysfunction 1 3 . Poor aqueous solubility of TDL is also related with poor in vitro dissolution rate which in turn results in poor oral bioavailability of TDL 2, 4 . Therefore, it is of great interest to enhance aqueous solubility and oral bioavailability of TDL in order to facilitate drug development process 1 4 . Recently, nanotechnology-based drug delivery systems DDS such as microemulsions, nanoemulsions, self-nanoemulsifying drug delivery systems SNEDDS , liposomes, transferosomes, niosomes, nanoparticles, nanocapsules, nanocrystals, polymeric micelles and dendrimers have been investigated extensively in literature for the enhancement of solubility, bioavailability and therapeutic efficacy of several poorly soluble drugs 5 10 .
Nanotechnology-based systems offered several advantages over conventional DDS 5, 6 . For solubility and dissolution enhancement of poorly soluble drugs, nanoemulsions and SNEDDS have also been investigated extensively in literature 11 19 . These lipid based carriers offered several advantages such as thermodynamic stability, great solubilization capacity, enhanced dissolution/permeation, enhanced bioavailability and ease of preparation 15 18 . The solubility of PG , caprylic/capric triglyceride Labrafac-Lipophile-WL 1349 and diethylene glycol monoethyl ether Transcutol-HP were obtained as kind gift samples from Gattefossé Cedex, France . Polyethylene glycol-400 PEG-400 , propylene glycol PG and octylphenol ethylene oxide condensate Triton-X100 were purchased from Fluka Chemicals Bucsh, Switzerland . Ready-to-use dialysis membranes MWCO 12 ,000 g/mole were purchased from Spectrum Medical Industries Mumbai, India . All the materials drug and chemicals used in the study were of high purity 99 .
Screening of components for TDL SNEDDS preparation
The selection of oil phase and cosurfactant were based on solubility of TDL in these components. The saturated solubility of TDL in different oils Capryol-PGMC, Capryol-90, Lauroglycol-FCC, Lauroglycol-90, Labrafac-PG, Labrafac-WL 1349 and Labrafil-M1944CS and different cosurfactants Transcutol-HP, PEG-400, PG and ethanol was determined by adding the excess amount of TDL in 2 ml of each selected oil or cosurfactant in 5 ml capacity vials. These mixtures were continuously mixed in an isothermal water shaker bath Julabo, MA maintained at 37 0.2 at 100 rpm for 72 h to reach equilibrium 16, 18 . After 72 h, each mixture was removed from the shaker and centrifuged at 5000 rpm for 20 min, filtered, diluted suitably with methanol and subjected for analysis of TDL content spectrophotometrically at 283 nm 22 . The criterion for selection of surfactant was based on the hydrophilic lipophilic balance HLB value and safety of surfactants.
2.3 Nanophasic map construction and optimization of TDL SNEDDS Based on solubility profile of TDL, Capryol-90 and Transcutol-HP were selected as oil phase and cosurfactant, respectively. Based on higher HLB value, Triton-X100 HLB 13.5 was selected as surfactant. Deionized water was selected as an aqueous phase as water is the frequently used aqueous phase in literature 16, 18 . Surfactant Triton-X100
and cosurfactant Transcutol-HP were mixed in the mass ratios of 1:0, 1:2, 1:3, 1:1, 2:1, and 3:1 in order to obtain various phase diagrams. For construction of pseudo-ternary phase diagrams, oil phase Capryol-90 and a specific ratio of surfactant to cosurfactant S mix were mixed thoroughly in 1:9 to 9:1 mass ratios. These mixtures of oil and S mix were then titrated with deionized water as reported in our previous articles 16, 18 . SNEDDS zones were marked on a pseudo-ternary phase diagram in case of each S mix .
Formulation development
The maximum SNEDDS zones were observed in 1:1 mass ratio of Triton-X100 and Transcutol-HP, hence this ratio was finely selected for the preparation of TDL SNEDDS. From the pseudo-ternary phase diagram, different formulations were selected. Almost entire range of SNEDDS zones in phase diagram was taken into account and varied oil compositions 8, 12, 16 and 20 w/w with minimum surfactant [15] [16] [17] [18] [19] [20] w/w and cosurfactant 15-20 w/w concentration were selected. 5 mg of TDL was directly solubilized in prepared SNEDDS to obtain drug-loaded SNEDDS Table 1 . 2.5 Thermodynamic stability and self-nanoemulsi cation tests In order to eliminate unstable formulations and to select stable one, the developed TDL SNEDDS F1-F8 were subjected to various thermodynamic stability tests. These tests were performed in terms of centrifugation, heating & cooling cycles and freeze-pump-thaw cycles 16, 18 . TDL SNEDDS F1-F8 were subjected to centrifugation at 5000 rpm for the period of 30 min. Prepared SNEDDS were further subjected to heating & cooling cycles 3 cycles between 4 and 50 for the period of 48 h. TDL SNEDDS which were found to be stable at above two stress conditions were further subjected to freeze-pump-thaw cycles 3 16 . The zeta potential ZP of TDL SNEDDS was also measured using Malvern Zetasizer using glass electrodes as reported previously 18 .
However, the viscosity of TDL SNEDDS F1-F8 was measured by Brookfield Viscometer Middleboro, MA as reported previously 24 .
T of TDL SNEDDS was measured spectrophotometerically SPUV-19, Dingelstadt, Germany at detection wavelength of 550 nm as reported previously 25 .
For determination of drug content, 1ml of each formulation F1-F8 was mixed with 10 ml methanol in a volumetric flask and shaken vigorously for 5 min. The drug contents were determined spectrophotometrically at 283 nm 22 .
Transmission electron microscopy TEM Tecnai TF20, Hillsboro, OR analysis was also performed to evaluate the surface morphology of optimized SNEDDS F5. TEM analysis was performed at 200 KV as reported in literature 26 .
In vitro drug release studies via dialysis membrane
Based on lower droplet sizes, lower PIs, lower viscosities, higher T and higher drug contents, TDL SNEDDS F5-F8 were selected for in vitro drug release studies. These studies were performed to compare the release of TDL from different SNEDDS and TDL suspension, all having same amount of TDL 5 mg . Drug release studies were carried out in 500 ml of phosphate buffer pH 6.8 dissolution media using United States Pharmacopoeia USP XXIV method at 100 rpm and 37 0.2 16 . One ml of each SNEDDS and TDL suspension were placed in ready-to-use dialysis bag. Three ml of samples were withdrawn at 0, 1, 2, 3, 6, 18 and 24 h and same amount of drug free phosphate buffer pH 6.8 was replaced every time 11 . The samples were analyzed for TDL content spectrophotometrically at 283 nm 22 .
Drug release kinetic
Various mathematical models such as zero order, first order, Higuchi, Hixon-Crowell and Korsemeyer-Peppas models have been developed for proposed mechanism of drug release from formulations 27 29 . The drug release data of TDL from SNEDDS and drug suspension was fitted into the following models:
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Where, Q 0 , Q t and Q ω are the amounts of TDL released initially, at time t and at time ω, respectively. C 0 and C represent the amounts of drug initially and at time t, respectively. W 0 and W t are the amounts of drug in formulations initially and at time t, respectively. K 0 , k 1 , k, k h and k p are zero order, first order, Higuchi, Hixon-Crowell and Korsemeyer-Peppas rate constants, respectively. The exponent n diffusion coefficient is used to characterize drug release mechanism.
2.9 Determination of TDL solubility in water and optimized SNEDDS F5 The saturated solubility of TDL in water and optimized SNEDDS F5 was determined spectrophotometrically at 283 nm 22 . The excess amount of TDL was taken in water and optimized SNEDDS F5 in glass vials in triplicate. The rest of the procedure was same as described under screening of components section.
Statistical analysis
Results were expressed as the mean standard deviation. The data of physicochemical parameters and drug release studies were statistically evaluated by one way analysis of variance ANOVA using Dunnett s test with the help of SPSS Version 11 software.
RESULTS

Screening of components for SNEDDS preparation
The saturated solubility data of TDL in different oils and cosurfactants at 37 is listed in Table 2 . Among different oils investigated, the highest solubility was observed in Capryol-90 7.88 0.34 mg/ml followed by Capryol-PGMC 5.94 0.28 mg/ml , Labrafil-M1944CS 5.42 0.18 mg/ml , Lauroglycol-90, Lauroglycol-FCC, Labrafac-PG and Labrafac-WL1349 Table 2 . However, the highest solubility was observed in Transcutol-HP 33.56 2.09 mg/ml among different cosurfactants followed by PEG-400, PG and ethanol. Based on solubility data of TDL, Capryol-90 and Transcutol-HP were selected as oil phase and cosurfactant, respectively. However, Triton-X100 and deionized water were selected as surfactant and aqueous phase, respectively.
Nanophasic map construction and optimization of
TDL SNEDDS Pseudo-ternary phase diagrams were constructed separately for each S mix in order to identify SNEDDS zones in the phase diagrams Fig. 1 . It was observed that when Triton-X100 was used alone S mix 1:0 , the SNEDDS zones in phase diagrams were very low Polyethylene glycol-400 (PEG-400), propylene glycol (PG), self-nanoemulsifying drug delivery system (SNEDDS) amount of Capryol-90 oil phase that was solubilized by this ratio was 9 w/w with very high amount of S mix 82 w/w . When 1:2 mass ratio of Triton-X100 to Transcutol-HP S mix was studied, the SNEDDS zones were found to be increased as compared 1:0 ratio Fig. 1B . The maximum amount of Capryol-90 that was solubilized by this ratio was 17 w/w by incorporating 66 w/w of S mix . When 1:1 mass ratio of Triton-X100 to Transcutol-HP was investigated, the SNEDDS zones were found to be increased rapidly as compared to 1:2 and 1:0 ratios Fig. 1C . The maximum amount of Capryol-90 that was solubilized by this ratio 1:1 was found to be 22 w/w by utilizing 52 w/w of S mix . However, when the mass ratios of 2:1 and 3:1 were studied, the SNEDDS zones were found to be decreased slightly as compared to 1:1 ratio Fig. 1D and E .
3.3 Thermodynamic stability and self-nanoemulsi cation tests Different thermodynamic stability tests viz. centrifugation, heating & cooling cycles and freeze-pump-thaw cycles were performed in order to eliminate unstable formulations and the results of these tests are listed in Table 3 16, 18, 23 .
Only stable formulations were selected for further characterization and their compositions are listed in Table 1 . Thermodynamically stable SNEDDS F1-F8 were further investigated for self-nanoemulsification test as it is mandatory for oral SNEDDS. This test was performed evaluate any phase separation or drug precipitation upon dilution with water 16, 23 . The results of these tests are listed in Table 3 . It was observed that formulations F1-F4 passed this test with grade B. However, formulations F5-F8 passed this test with grade A.
Physicochemical characterization of TDL SNEDDS
The results of physicochemical characterization are listed in Table 4 . The droplet size of SNEDDS F1-F8 was observed in the range 64.7-211.8 nm. It was observed that when the concentration of S mix was held constant at 30 w/w and the concentration of Capryol-90 oil phase was varied from 8 to 20 w/w F1-F4 , the droplet size was found to be increased significantly p 0.05 . Similarly, when the concentration of S mix was held constant at 40 w/w F5-F8 and the concentration of Capryol-90 was varied from 8 to 20 w/w F5-F8 , the droplet size was found to be increased again The purpose of TEM analysis was to evaluate the surface morphology and shape of droplets of optimized SNEDDS F5. Photomicrograph of optimized SNEDDS F5 was taken and interpreted for morphology. The size of all droplets was found to be less than 100 nm Fig. 2 . 
√ (Passed the respective test), cent. (centrifugation), H&T (heating and cooling cycles), FPT (freeze-pump-thaw cycles)
In vitro drug release studies
The results of TDL release from SNEDDS and drug suspension are presented in Fig. 3 . It was observed that initial release of TDL from all SNEDDS and drug suspension was rapid immediate release profile . The release profile of TDL from all SNEDDS was significant as compared to drug suspension p 0.05 . More than 60 of TDL was found to be released from all SNEDDS as compared to 8.2 from drug suspension after 6 h of study Fig. 3 . After 6 h, all SNEDDS and drug suspension showed slower release of TDL sustained release profile . The highest drug release of TDL was observed with formulation F5 Fig. 3 . The amount of TDL that was released from F5 after 24 h of study was found to be 96.6 as compared to 12.4 from drug suspension. Around 84 of TDL was released from F5 after 6 h of study. However, the lowest drug release profile was observed in drug suspension.
Drug release kinetic
Release kinetic parameters for different SNEDDS F5-F8 and drug suspension were calculated using various mathematical models and results are listed in Table 5 . The release from formulations F5, F6, F7 and drug suspension followed Korsemeyer-Peppas model with non-Fickian diffusion mechanism. However, the release from formulation F8 followed Korsemeyer-Peppas model with supercase II transport mechanism. 3.7 Determination of TDL solubility in water and optimized SNEDDS F5 The results of solubility studies of TDL in water and optimized SNEDDS F5 are listed in Table 2 . The saturated solubility of TDL in water was observed as 0.02 mg/ml at 37 . However, the saturated solubility of TDL in optimized SNEDDS F5 was found to be 28.68 mg/ml at 37 Table  2 , indicating TDL is present in its molecular state due to stable formation of SNEDDS 2 . Therefore, more than 25 mg of TDL could be loaded in 1 ml formulation of SNEDDS F5.
DISCUSSION
The solubility of drug TDL in oil phase is the most important step for screening of oils 10, 12 . However, several methods have been reported for screening of surfactants and cosurfactants including solubility 16, 18, 30 33 . In present study, the oils and cosurfactants were screened based on solubility of TDL in these components. However, the surfactant was selected based on its safety and higher HLB value because surfactants with higher HLB values favor the formation oil-in-water nanoemulsions. In present study, Triton-X100 was selected as surfactant because of its higher HLB value, safety, biodegradability and it has been investigated rarely as compared to other higher HLB surfactants such as Tween-80, Cremophor-EL and Labrasol 16 19 .
With regard to pseudo-ternary phase diagrams, maximum SNEDDS zones were observed in 1:1 S mix ratio of Triton-X100 to Transcutol-HP Fig. 1C . Therefore, different formulations F1-F8 with different concentrations of oil phase 8, 12, 16 and 20 w/w and surfactant phase 30 and 40 w/w were precisely selected from Fig. 1C . 5 mg of TDL was directly solubilized in each SNEDDS for further evaluation. The composition of these SNEDDS is listed in of Capryol-90. Two steps release profile of TDL from SNEDDS and drug suspension indicated diffusion controlled dissolution rate of TDL 18, 34 . Drug release kinetic studies showed that all formulations followed KorsemeyerPeppas model. If the value of exponential n diffusion coefficient is equal to 0.5, it indicates Fickian diffusion mechanism. However, the value of n greater than 0.5 but less than 1.0 indicates non-Ficknian diffusion mechanism. On the other hand, the value of n greater than 1.0 indicates supercase II transport mechanism 27 . The value of n in formulations F5-F7 and drug suspension were observed in the range of 0.705-0.944, indicating non-Ficknian diffusion mechanism. However, the value of n for F8 was found to be 1.018, indicating supercase II transport mechanism. Based on highest drug release 96.6 , lowest droplet size 64.7 nm , lowest PI 0.112 , lowest viscosity 35.6 cp , highest T 99.1 , highest drug content 98.9 and lower concentration of Capryol-90, formulation F5 was selected as an optimized formulation of TDL for further evaluation.
The poor aqueous solubility of drugs is the main cause of their formulation development which is directly related with dissolution rate and bioavailability of such drugs 18, 35 .
Therefore, solubility enhancement of such drugs is of great significance in order to eliminate any barrier associated with formulation development. Hence, the solubility of poorly soluble drug TDL was enhanced by SNEDDS in present study. The enhancement in TDL solubility was observed as 1434 folds in optimized SNEDDS F5 as compared to its aqueous solubility 0.02 mg/ml . The enhanced solubility of TDL could be due to the molecular attractions between the molecules of TDL and the molecules of solvents such as Capryol-90, Triton-X100 and Transcutol-HP present in SNEDDS. The molecules of TDL could experience various kind of forces such as hydrophobic interactions, electrostatic forces and stereoscopic effects in solubilization process. TDL molecules have amide amine groups which could allow the dissolution of TDL molecules to breakdown the alignment of the sample matrices, which could further reduce the degree of order in the system and results in enhanced solubility of TDL. Therefore, the enhancement in TDL solubility in optimized SNEDDS F5 was possible due to the combined effects of Capryol-90, Triton-X100 and Transcutol-HP.
CONCLUSIONS
Based on lowest droplet size 64.7 nm , lowest PI 0.112 , lowest viscosity 35.6 cp , highest T 99.1 , highest drug content 98. 9 , lower concentration of Capryol-90 8 w/w , optimum surfactant Triton-X100, 20 w/w & cosurfactant concentrations Transcutol-HP, 20 w/w and highest drug release 96. 6 , SNEDDS F5 has been optimized as an effective formulation of tadalafil.
From these results, it was concluded that SNEDDS could be successfully used for solubility and dissolution enhancement of tadalafil. However, further pharmacodynamic and pharmacokinetic investigations are required to enhance oral bioavailability and therapeutic efficacy of tadalafil in comparison with marketed formulations. Pharmacodynamic and pharmacokinetic investigations are in process in the laboratory.
